{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.1","upperLimit":"126","value":"104"},{"groupId":"OG001","lowerLimit":"147","upperLimit":"200","value":"171"},{"groupId":"OG002","lowerLimit":"147","upperLimit":"230","value":"184"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"description":"Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. AUC(0-t) is defined as the area under the concentration-time curve over the dosing interval. The AUC(0-t) for a 50mg dose was estimated for each cohort. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received eltrombopag in Part 1 continued on the same dose in Part 2 unless adjustments were warranted according to the dosing guidelines. Participants who received placebo in Part 1 received Eltrombopag as per age criteria as follows:body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD.","id":"OG000","title":"Eltrombopag Cohort 1 (12-17 Years)"},{"description":"Participants who received eltrombopag in Part 1 continued on the same dose in Part 2 unless adjustments were warranted according to the dosing guidelines. Participants who received placebo in Part 1 received Eltrombopag as per age criteria as follows: body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD.","id":"OG001","title":"Eltrombopag Cohort 2 (6-11 Years)"},{"description":"Participants who received eltrombopag in Part 1 continued on the same dose in Part 2 unless adjustments were warranted according to the dosing guidelines. Participants who received placebo in Part 1 received Eltrombopag 1.2 mg/kg QD and; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day.","id":"OG002","title":"Eltrombopag Cohort 3 (1-5 Years)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population. Only those participants who provided pharmacokinetic samples were analyzed","reportingStatus":"POSTED","timeFrame":"Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)","title":"Pharmacokinetic (PK) Assessments for Eltrombopag for AUC (0-t)","type":"SECONDARY","unitOfMeasure":"micrograms*hour per milliliter (ug.h/mL)"}